Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydroxyflutamide intraprostatic - LIDDS

Next Previous
X
Search
Drug Profile

Hydroxyflutamide intraprostatic - LIDDS

Alternative Names: 2-hydroxyflutamide - LIDDS; Liproca Depot; Liproca® Depot - LIDDS; NZ 2 HOF; OH-flutamide

Latest Information Update: 26 Feb 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LIDDS
  • Developer LIDDS; Uppsala University
  • Class Anilides; Antiandrogens; Antineoplastics; Small molecules
  • Mechanism of Action Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 23 Feb 2024 LIDDS plans to commence a Phase III clinical trial in Prostate cancer, a decision that has been informed by an advisory meeting with the EMA
  • 08 Jul 2022 LIDDS has patent protection for NanoZolid® production process in Israel
  • 08 Jul 2022 LIDDS has patent protection for NanoZolid® production process in Japan, South Korea, China, Russia, Australia, India, South Africa and Singapore

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top